While I agree with you that solutions to engineering challenges are not a simple matter of throwing money at each issue, I think it's important to further refine two problems you bring up.
Finding correct ligands is less a challenge than you present. Specific and very effective ligands have been identified and snipped for attachment against a dozen viruses. Rabies, flu, HIV and HSV are the best known. Further, highly dangerous viruses are that way because they act and are structured differently from those listed above. Ebola virion is about 10 times larger than rabies, flu, etc. On top of that, Ebola has weird and inconsistent shapes in addition to the biggest challenge, the shedase cloud which is evolved to counter natural immune responses.
For more common and far less deadly infectious diseases, ligands are readily available and easily enough attached to base micelles. The biggest challenge is batch consistency. Gleaming from 12 years of filings one can easily draw some conclusions. There seems to be challenge in reengineering production for batches above 200 mg. It would appear that heat transfer and absorption, formation of micelles, and fluid dynamics all shift immediately above 200mg. And at about 200mg consistency issues begin to appear. My opinion is that this was an unanticipated problem that could not reveal until the new, larger equipment was in place, something that took about 10 of those 12 years to become evident.
Market Data 
Markets 
AI
